Last reviewed · How we verify

NCT03086876

Evaluation of Parent Intervention for Challenging Behaviour in Children With Intellectual Disabilities (EPICC-ID)

Completed NA Last updated 21 April 2022
What this trial tests

NA trial testing Level 4 Stepping Stones Triple P (SSTP) in Challenging Behaviour in 261 participants. Completed in 31 March 2022.

Timeline
1 June 2017
Primary endpoint
17 December 2021
31 March 2022

Quick facts

Lead sponsorUniversity College, London
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment261
Start date1 June 2017
Primary completion17 December 2021
Estimated completion31 March 2022
Sites4 locations across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University College, London

Who can join

Adults 30 Months to 59 Months, any sex, with Challenging Behaviour. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Children with intellectual disabilities are likely to present with challenging behaviour. Parent mediated interventions have shown utility in influencing child behaviour, although there is a paucity of UK research into challenging behaviour interventions in this population. NICE guidelines favour Stepping Stones Triple P (SSTP) as a challenging behaviour intervention and this trial aims to evaluate its clinical and cost effectiveness in preschool children with moderate to severe intellectual disabilities.The trial launched in 2017 at four sites across England, with the aim of recruiting 258 participants (aged 30-59 months). The Intervention Group receive nine weeks of SSTP parenting therapy (six group sessions and three individualised face to face or telephone sessions) in addition to Treatment as Usual (TAU) whilst the TAU group receive available services in each location. Both study groups undergo the study measurements at baseline and at four and twelve months. Outcome measures include parent reports and structured observations of behaviour. Service use and health related quality of life data is also being collected to carry out a cost effectiveness and utility evaluation. Findings from this study will inform policy regarding interventions for challenging behaviour in young children with moderate to severe intellectual disabilities.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Clinical and cost effectiveness of a parent mediated intervention to reduce challenging behaviour in pre-schoolers with moderate to severe intellectual disability (EPICC-ID) study protocol: a multi-centre, parallel-group randomised controlled trial.
    Farris O, Royston R, Absoud M, Ambler G, et al · · 2020 · cited 6× · PMID 32000729 · DOI 10.1186/s12888-020-2451-6
  2. Evaluation of adapted parent training for challenging behaviour in pre-school children with moderate to severe intellectual developmental disabilities: A randomised controlled trial.
    Royston R, Absoud M, Ambler G, Barnes J, et al · · 2024 · cited 3× · PMID 39137195 · DOI 10.1371/journal.pone.0306182
  3. Clinical and cost-effectiveness of an adapted intervention for preschoolers with moderate to severe intellectual disabilities displaying behaviours that challenge: the EPICC-ID RCT.
    Ondruskova T, Royston R, Absoud M, Ambler G, et al · · 2024 · cited 2× · PMID 38329108 · DOI 10.3310/jkty6144
  4. Process evaluation of a parenting intervention for pre-schoolers with intellectual disabilities who display behaviours that challenge in the UK.
    Ondrušková T, Oulton K, Royston R, EPICC‐ID Research Group, et al · · 2024 · cited 1× · PMID 39045819 · DOI 10.1111/jar.13263

Verify or expand the search:

Other University College, London trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03086876.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing